Ionic Transport Assays uses the SpectraMax i3 reader to study drug candidate-induced cardiotoxicity in stem cell-derived cardiomyocytes

Ionic Transport Assays

John Gibson, PhD, FAHA Yimei Yue, Research Associate

SpectraMax i3x Multi-Mode Microplate Reader

The Challenge

Ionic Transport Assays Inc. is a contract research organization located in St Louis, MO. Since 2011, Ionic Transport Assays has performed multiple assays for customers on human induced pluripotent stem cell cardiomyocytes (hIPSC–CM). This work is directed to meet the challenges of the Safety Pharmacology Comprehensive in vitro Proarrhythmia Assessment (CiPA) proposed by the FDA for new drug development.

Ionic Transport Assays uses SpectraMax i3 Reader

The Solution

Ionic Transport Assays uses the SpectraMax® i3 Multi-Mode Microplate Reader to measure intracellular calcium fluoresence as a marker of cardiac contraction, electrophysiology and toxicity in hIPSC cardiomyocytes. This high throughput pre-clinical testing uses relevant human tissue to identify compounds with cardiac issues early in the drug development pipeline, saving customers’ time and money.